Rani Therapeutics Q2 2026 net loss narrows to $8.4 million; cash rises to $53.4 million
Rani Therapeutics reported second-quarter 2026 results with contract revenue of $1.7 million, up from none a year earlier, and a net loss of $8.4 million, down from $11.2 million. Cash and marketable securities rose to $53.4 million, which the company says will fund operations at least through 2027, though the net loss attributable to Rani shareholders increased to $7.4 million from $6.7 million.
Key points
- Q2 2026 contract revenue was $1.7 million, compared with no contract revenue in Q2 2025, primarily from the Chugai collaboration.
- Net loss per Class A share attributable to Rani was $(0.04) for Q2 2026, compared with $(0.18) for Q2 2025.
- Cash, cash equivalents and marketable securities totaled $53.4 million at June 30, 2026, up from $43.4 million at March 31, 2026, after a $20.0 million registered direct offering in May 2026.
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.